SRCIN1 and cancer: For example, in ovarian cancer, miR-665 targets SRCIN1, which inhibits SRC kinases to enhance the activation of MAPK/ERK and the mTOR axis to promote epithelial–mesenchymal transition (EMT) and cancer progression [26].